Drug intelligence / Profile preview

YR-101

Development stage: Preclinical
Lead developer: Hangzhou Yirui Pharmaceutical Technology
Modality: Small Molecules

Overview

YR-101 is a small molecule drug under development by Hangzhou Yirui Pharmaceutical Technology (also referred to as YIRUI Pharmaceutical Technology) for the treatment of diabetic nephropathies. It acts as an ion channel inhibitor, specifically functioning as an ion channel antagonist. The drug is classified as a new molecular entity and is currently in preclinical development. Its primary therapeutic area is endocrinology and metabolic disease, with a focus on urogenital diseases such as diabetic nephropathy. Clinical trials are planned to begin in the second half of 2025, with investigational new drug application submission targeted for the first half of 2025[1][2][4].

Beyond the preview

Go deeper on YR-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YR-101.

Explore the full profile